Tag: dMMR advanced solid tumors

Home / dMMR advanced solid tumors

Categories

Dostarlimab-gxly receives accelerated approval from the FDA for dMMR advanced solid tumours

August 2021: Dostarlimab-gxly (Jemperli, GlaxoSmithKline LLC) was given accelerated approval by the Food and Drug Administration for adult patients with mismatch repair deficient (dMMR) recurrent or a...
dmmr-advanced-solid-tumors

Scan the code